Hpd-l1-binding sdAbs were prepared and injected intravenously in mice, and results confirmed that this antibody was able to block PD-1/PD-L1, enhance the T cell receptor signaling pathway, and kill tumor cells. This evidence concerns the gene CD274 and neoplasm.